Trevi Therapeutics to Participate in Upcoming April Investor Conferences [Yahoo! Finance]
Trevi Therapeutics to Participate in Upcoming April Investor Conferences
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock, up previously from $11.00.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.50 price target on the stock.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target lowered by analysts at Needham & Company LLC from $25.00 to $24.00. They now have a "buy" rating on the stock.